Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

J&J presents positive phase 3 results for Darzalex Faspro in smouldering multiple myeloma

The early precursor of active disease accounts for 15% of all newly-diagnosed multiple myeloma cases

- PMLiVE

Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma

Approximately 160,000 cases of the aggressive blood cancer are diagnosed globally every year

- PMLiVE

Putting EU Lab Day on the Map

EU Lab Day 2024 made an impact - reaching over 1.7million people through media and social.

EatMoreFruit

- PMLiVE

Want to Tell Your Story Differently in 2025?

From animation and gamification, to events, influencers, opinion leaders, and chatbots; there are tools and tactics which can engage health professionals, payors, patients and consumers. At EatMoreFruit we like to...

EatMoreFruit

- PMLiVE

Sanofi’s rilzabrutinib shows promise in phase 3 immune thrombocytopenia study

Approximately 9.5 per 100,000 people in the US are affected by the rare autoimmune disorder

regeneron headquarters

Regeneron shares positive late-stage results for poze-cemdi in rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects up to 1.5 people per million in the US

IRA payer survey results

Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act

To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to...

Genesis Research Group

- PMLiVE

GSK and Rgenta to develop RNA-targeting small molecules in deal worth up to $500m per target

The alliance is aimed at advancing treatments for multiple disease areas, including oncology

- PMLiVE

LEO Pharma’s Anzupgo cream granted MHRA approval to treat chronic hand eczema

Anzupgo is the first topical pan-JAK inhibitor approved specifically for adults with moderate-to-severe cases

- PMLiVE

Amgen announces $1bn investment to establish new US drug manufacturing facility

The expansion in North Carolina builds on the company’s previous $550m commitment in the area

- PMLiVE

ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

The research could pave the way for the development of new drugs that prevent drug resistance

- PMLiVE

AstraZeneca appoints Iskra Reic as executive vice president international

Reic has been serving as executive vice president of the company's vaccines and immune therapies unit

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links